First Patients Recruited In The Extended Phase III Programme Using Lu AA21004 In MDD

First Patients Recruited In The Extended Phase III Programme Using Lu AA21004 In MDD
H. Lundbeck A/S (Lundbeck) announced that the first patients have been recruited and dosed in the new phase III programme using Lu AA21004 in major depression (MDD). The first patients have been recruited in Finland. As previously communicated filing of Lu AA21004 is anticipated in 2012. The extended phase III programme for Lu AA21004 is based on clinical data obtained until now…

Read more on Medical News Today

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA
Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced plans to submit a Phase III trial design for DAVANAT to the U.S. Food and Drug Administration during the second half of 2010. The Company has added the talent of Peter G. Traber, M.D., to its FDA approval strategy and trial design team.

Read more on News-Medical-Net

Active Biotech to Present at the Rodman & Renshaw 6th Annual Global Healthcare Conference

Active Biotech to Present at the Rodman & Renshaw 6th Annual Global Healthcare Conference
LUND, SWEDEN–(Marketwire – 05/17/10) – Active Biotech (NASDAQ OMX Nordic: ACTI) is scheduled to present today at the Rodman & Renshaw 6th Annual Global Healthcare Conference at the Grosvenor House Hotel in London. During the presentation, an update regarding Active Biotech’s development programs will be provided. The presentation will include the Phase III project laquinimod, a novel oral …

Read more on Marketwire via Yahoo! Finance

Avexa Halts HIV Drug Trials: The Future Decoded

Avexa Halts HIV Drug Trials: The Future Decoded
Melbourne-based biotech Avexa has announced the closure of its lead HIV program for apricitabine after failing to attract a licensing partner for the Phase III drug.

Read more on BioresearchOnline

Active Biotech AB Interim report January – March 2010

Active Biotech AB Interim report January – March 2010
LUND, SWEDEN–(Marketwire – 04/22/10) – Laquinimod – Teva extends its marketing and distribution rights for laquinimod TASQ – preparations for Phase III trials under way ANYARA – exploratory combination data presented 57-57 – exploratory clinical trial in progress ISI – project proceeding according to plan RhuDex – preclinical studies in progress Net sales of SEK 2.8 M (2.2) Operating loss of …

Read more on Marketwire via Yahoo! Finance

Next Page »